Protalix BioTherapeutics Reports First Quarter 2020 Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Protalix BioTherapeutics (PLX) Tops Q1 EPS by 40c, Revenues Beat
June 1, 2020 6:53 AM EDTProtalix BioTherapeutics (NYSE: PLX) reported Q1 EPS of $0.10, $0.40 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.65 million versus the consensus estimate of $6.6 million.
"The first quarter of 2020 has most certainly been transformational for Protalix, despite the COVID-19... More
